Other GLS inhibitors, such as IACS-6274 in head and neck squamous cell carcinoma (HNSCC) and IPN60090 in non-small cell lung cancer (NSCLC) and ovarian cancer, have demonstrated efficacy in preclinical models (160) (161). Here, GLS is linked to non-small cell lung carcinoma.